Kitron: KIT – Utstedelse av aksjer under aksjeincentivprogram
(2022-08-30) Det vises til Kitron ASAs tidligere offentliggjøringer knyttet til aksjeincentivprogrammet i selskapet. Kitron har mottatt meldinger om utøvelse av opsjoner fra deltakere i aksjeincentivprogrammet og Kitron's styre har vedtatt å utstede 676 664 nye aksjer. Aksjene utstedes til opsjonshaverne til en tegningskurs på NOK 0,10 per aksje i henhold til styrefullmakten vedtatt av Kitrons generalforsamling avholdt 27. april 2022.
I tillegg har Kitron vedtatt å konvertere 493 336 utøvde opsjoner under aksjeincentivprogrammet mot kontantoppgjør. Kontantoppgjøret vil benyttes til å dekke skatteplikten for opsjonseierne som skal trekkes av Kitron etter utøvelse av opsjonene. Konvertering av opsjonene er gjort til NOK 19,90 som tilsvarer sluttkurs på Oslo Børs 30. august 2022 med fratrekk for tegningskurs på NOK 0,10.
Følgende primærinnsidere i Kitron har utøvet opsjoner og tegnet nye aksjer i kapitalforhøyelsen:
| Antall aksjer tegnet | Antall opsjoner konvertert mot kontantoppgjør | |
| Peter Nilsson, CEO and President | 183 920 | 166 080 |
| Cathrin Nylander, CFO | 79 622 | 70 378 |
| Kristoffer Asklöv, COO | 50 000 | 0 |
| Hans Petter Thomassen, Managing Director Kitron Norway & VP North America | 82 602 | 67 398 |
| Mindaugas Sestokas, Managing Director Kitron Lithuania & VP Central Eastern Europe | 102 000 | 48 000 |
| Stefan Hansson Mutas, Managing Director Kitron Sweden | 76 020 | 73 980 |
| Zygimantas Dirse, Managing Director Kitron China | 82 500 | 67 500 |
Primærinnsidermeldinger i henhold til markedsmisbruksforordningen artikkel 19 er vedlagt.
Kitron har videre vedtatt å benytte en rett etter aksjeincentivprogrammet til å innføre omsetningsbegrensninger på aksjene som utstedes i kapitalforhøyelsen beskrevet over. Alle aksjene vil være gjenstand for en bindingstid på tre år, men slik at de to siste årene vil en åttendedel av det totale antallet nye aksjer frigis kvartalsvis og bli omsettelige.
For ytterligere informasjon, vennligst kontakt:
Tuomo Lähdesmäki, Styreleder i Kitron
Tel.: +358-50-5879648
E-post: investorrelations@kitron.com
Kitron er et ledende skandinavisk foretak innen produksjon av elektronikk og relaterte tjenester for sektorene Konnektivitet, Elektrifisering, Industri, Medisinsk utstyr og Forsvar/Luftfart. Konsernet har virksomhet i Norge, Sverige, Danmark, Litauen, Tyskland, Polen, Tsjekkia, Kina og USA. Inkludert oppkjøpet av BB Electronics i januar 2022, har Kitron rundt 2.800 ansatte, og proforma driftsinntekter var rundt 5 milliarder kroner i 2021.
Denne informasjonen er offentliggjort av Selskapet i henhold til EUs markedsmisbruksforordning artikkel 5, supplementert av delegert kommisjonsforordning (EU) 2016/1052, og er underlagt kravene til offentliggjøring i henhold til verdipapirhandelloven § 5-12.
Vedlegg
Hvis du vil se dette innholdet fra www.globenewswire.com, gi ditt samtykke øverst på denne siden.Hvis du vil se dette innholdet fra ml-eu.globenewswire.com, gi ditt samtykke øverst på denne siden.
Om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeldinger fra GlobeNewswire by notified
Registrer deg med din e-postadresse under for å få de nyeste sakene fra GlobeNewswire by notified på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra GlobeNewswire by notified
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares24.4.2024 03:36:40 CEST | Press release
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about April 26, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 1,621,621 ADSs at the public offering price, less underwriting discounts and commissions. Goldman Sachs, Leerink Partners, Eve
UK businesses must prioritise payment technology to build customer loyalty and stay competitive: New research from Lloyds Bank and FreedomPay24.4.2024 01:01:00 CEST | Press release
London, United Kingdom, April 23, 2024 (GLOBE NEWSWIRE) -- Less than a third (27%) of businesses are confident they offer seamless payments experiences.Almost two-thirds of businesses (59%) across Retail, Food & Beverages and Hospitality believe a good checkout experience offers the same competitive advantage as having the best products.Customer preference is the factor most likely to influence businesses’ investment in payment technologies. New research from Lloyds Bank and FreedomPay highlights the importance of UK businesses investing in new payment technology. Two-thirds (59%) of UK Retail, Food & Beverage (F&B) and Hospitality companies were found to already put payments at the heart of their customer experience strategy, reflecting the growing importance of payment options to customers. For retail-focused businesses, 59% believe that a good checkout experience is essential to building customer loyalty, with respondents believing it is as much a competitive advantage as having the
Millicom announces the re-issuance of its AGM and EGM Convening Notice23.4.2024 22:30:00 CEST | Press release
Millicom announces the re-issuance of its AGM and EGM Convening Notice Luxembourg, April 23, 2024 – Millicom today announced the re-issuance of the Convening Notice to its Annual General Meeting (“AGM”) and Extraordinary General Meeting (“EGM”) of Shareholders which will be held on May 23, 2024. The Convening Notice contains a rectified note to the AGM agenda item 20 (Share Repurchase Plan). All other items of the AGM and EGM remain unchanged. The Convening Notice is appended to this press release and available on the company’s website at: https://www.millicom.com/our-company/corporate-governance/shareholder-meetings/. AGM voting materials have been updated to reflect the rectified note. -END- For further information, please contact AGM/EGM Inquiries: Patrick Gill, Company Secretary +352 27 759 603 Maria Florencia Maiori, Senior Legal Counsel information@millicom.comPress: Sofia Corral, Director Corporate Communications press@millicom.comInvestors: Michel Morin, VP Investor Relations i
CNH announces signing of a €3.25 billion committed revolving credit facility23.4.2024 22:30:00 CEST | Press release
CNH announces signing of a €3.25 billion committed revolving credit facility Basildon, April 23, 2024 On April 19, 2024, CNH (NYSE: CNHI) signed a €3.25 billion committed revolving credit facility, intended for general corporate purposes of the Company. The facility, entered into with a group of 18 banks providing aggregate commitments in excess of €3.5 billion, has a 5-year tenor with two extension options of one year each, exercisable on the first and second anniversary of the signing date. It replaces an existing 5-year €4 billion facility due to mature in March 2026. The final size of the facility, set at €3.25 billion, aligns with reduced funding needs following the demerger of Iveco Group. The transaction confirms the strong support of a large panel of international key relationship banks for the Company. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Produc
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares23.4.2024 22:17:37 CEST | Press release
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs and Leerink Partners are acting as lead joint book-running managers for the proposed offering. Evercore ISI, Guggenheim Securities and BMO Capital Markets are also acting as joint book-running mana